Accelr8 Announces Patent Filing for Rapid DNA and Protein Detection

    DENVER, July 30 /PRNewswire-FirstCall/ -- Accelr8 Technology Corporation
 (OTC Bulletin Board:   ACLY) announced today that the company filed a
 provisional patent application for microarraying methods to rapidly detect and
 quantitatively measure nucleic acids and proteins in a biological sample.  The
 new technology, named YoDx(TM), complements and enhances the capabilities of
 Accelr8's QuanDx(TM) light scattering detection technology.  Microarraying and
 related analyses are important in research for drug discovery, molecular
 diagnostics, food-borne pathogen detection and bio-defense.
     The company has established two major performance objectives for the new
 technology.  The first is to shorten the incubation times of a typical DNA or
 protein assay by a factor of 10-fold or more, relative to current technology.
 The second is to increase sensitivity by a factor of 100-fold or more.
     The company's scientists expect the new technology to shorten analysis
 incubation times by rapidly agitating the sample mixture and rapidly
 concentrating sample target molecules into a reaction zone.  At the reaction
 zone, target molecules in the sample bind to probe molecules.  The scientists
 expect these rapid processes to drive target binding at least ten times faster
 than with current methods.
     Increased sensitivity reduces the amount of sample and amplification
 needed to provide reliable results.  Amplification is a costly and time-
 consuming process, can contribute to errors, and is often difficult to
 quantify.  YoDx will use the company's light scattering nano-particle counting
 technology in combination with Accelr8's OptiChem(TM) surface chemistry to
 provide accurate quantitation and very low background interference.  New
 improvements covered in the patent application include methods to reduce
 background interference and simplify nano-particle detection.  Company
 scientists expect the sensitivity of the improved device to substantially
 exceed that of the fluorescence methods that dominate today's applications.
     According to Thomas Geimer, Accelr8's Chairman and CEO, "we believe that
 emerging markets such as molecular diagnostics will require analytical systems
 that provide higher sensitivity, quicker results, better data reliability, and
 significantly lower cost as compared to today's PCR and immunoassay
 technologies.  Markets such as drug discovery will require similar advances in
 methods to use with their high-throughput robotics to shorten the discovery
 cycle.  We believe that YoDx will help us achieve these goals in a next-
 generation system that will strongly differentiate us from the competition.
 In addition, we believe that YoDx technology will give us powerful
 capabilities for portable point-of-care devices.  YoDx represents our next
 step in our plan to provide advanced quantitative capabilities to the bio-
 analytical industry."
 
     Certain statements in this news release may be "forward-looking
 statements" within the meaning of Section 27A of the Securities Act of 1933,
 as amended, and Section 21E of the Securities Exchange Act of 1934, as
 amended.  Statements regarding future prospects and developments are based
 upon current expectations and involve certain risks and uncertainties that
 could cause actual results and developments to differ materially from the
 forward-looking statement, including those detailed in the company's filings
 with the Securities and Exchange Commission.
 
 

SOURCE  Accelr8 Technology Corporation